Home › Funds › Tetragon Partners GP Ltd › RARE
Tetragon Partners GP Ltd position in RARE
ULTRAGENYX PHARMACEUTICAL IN · Health Care
Tetragon Partners GP Ltd reported holding 100,000 shares of RARE (ULTRAGENYX PHARMACEUTICAL IN) in its Q2 2026 13F filing — a position valued at US$3.3M, representing 0.54% of its reported portfolio and ranking #26 among its reported holdings. Tetragon Partners GP Ltd has disclosed RARE holdings in 3 of the last 4 reported quarters, going back to Q3 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Tetragon Partners GP Ltd's RARE position evolved
Tetragon Partners GP Ltd first disclosed a stake in RARE in Q3 2025 at 17,718 shares (US$533K). The position peaked in Q2 2026 at 100,000 shares, worth US$3.3M. Across 3 filings, Tetragon Partners GP Ltd increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 100,000 shares valued at US$3.3M — an increase of 60,527 shares quarter over quarter.. Notable position changes include a 153% increase in Q2 2026 (shares fell 55% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2025 | 17.72K | $532.96K | New |
| Q1 2026 | 39.47K | $826.96K | New |
| Q2 2026 | 100.00K | $3.34M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About RARE and 13F data
RARE (ULTRAGENYX PHARMACEUTICAL IN) is a Health Care company. 27 other funds we track also report a position in RARE — the largest reported positions include RTW INVESTMENTS, LP (US$260.3M), SANDS CAPITAL MANAGEMENT, LLC (US$105.5M), FRONTIER CAPITAL MANAGEMENT CO LLC (US$95.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding RARE
- RTW INVESTMENTS, LP 7.80M sh · $260.34M · Q2 2026
- SANDS CAPITAL MANAGEMENT, LLC 3.16M sh · $105.46M · Q2 2026
- FRONTIER CAPITAL MANAGEMENT CO LLC 2.85M sh · $95.09M · Q2 2026
- Bellevue Group AG 1.98M sh · $66.20M · Q2 2026
- MPM BioImpact LLC 1.42M sh · $47.35M · Q2 2026
More on Tetragon Partners GP Ltd
FAQ
How long has Tetragon Partners GP Ltd held RARE?
Tetragon Partners GP Ltd has disclosed RARE holdings in 3 of the last 4 reported quarters, going back to Q3 2025.
What is Tetragon Partners GP Ltd's current position in RARE?
As of Q2 2026, Tetragon Partners GP Ltd holds 100.00K shares of RARE (ULTRAGENYX PHARMACEUTICAL IN), valued at $3.34M, representing 0.54% of its reported portfolio and ranking #26.
Has Tetragon Partners GP Ltd been buying or selling RARE?
In the latest 13F filing (Q2 2026), Tetragon Partners GP Ltd increased its position in RARE. The position peaked in Q2 2026 at 100.00K shares.
Which other funds hold RARE?
Other major institutional holders of RARE include RTW INVESTMENTS, LP, SANDS CAPITAL MANAGEMENT, LLC, FRONTIER CAPITAL MANAGEMENT CO LLC, among 27 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.